| Date | Title | Description |
| 03.04.2017 | Sucampo Pharmaceuticals Acquires Vtesse, for $200M | Vtesse, Inc., a Gaithersburg, Maryland-based rare disease company, has been acquired by Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP), for an upfront consideration of $200m.
Sucampo funded the acquisition through the issuance of 2,782,678 sh... |
| 03.04.2017 | Cydan Development Announces the Acquisition of Its First Rare Disease Spin-out, Vtesse, Inc. by Sucampo Pharmaceuticals, Inc. | Link to Release
Cambridge, Mass., April 3, 2017 – Cydan Development, Inc., an orphan drug accelerator dedicated to creating therapies that improve the lives of people living with rare genetic diseases, today announces that Vtesse, Inc., ... |
| 26.07.2016 | Vtesse Secures Additional $17M in Series A Extension | Gaithersburg, MD – Vtesse, Inc. a company committed to developing drugs that will benefit patients with extremely rare, life-threatening diseases, announced today that it has secured $17 million in additional Series A funding in support of ... |
| 25.07.2016 | Vtesse Secures Additional $17 Million in Series A Extension | Vtesse, Inc., a company committed to developing drugs that will benefit patients with extremely rare, life-threatening diseases, announced today that it has secured $17 million in additional Series A funding in support of its global, pivota... |
| 25.07.2016 | Vtesse Secures $17M in Series A Funding | Vtesse, Inc., a Gaithersburg, Md.-based developer of drugs that will benefit patients with extremely rare, life-threatening diseases, secured $17m in additional Series A funding.
Backers included Alexandria Venture Investments, Bay City Cap... |
| 25.07.2016 | Vtesse Inks Additional $17M Series A Extension |
GAITHERSBURG, MD, Company committed to developing drugs that will benefit patients with extremely rare, life-threatening diseases, has secured $17 million in additional Series A funding.
>> Click here for more funding data on Vtess... |
| 19.08.2015 | Rare disease companies must compete for clinical trial participants | This could be a real blow for patient communities, who have been the driving force behind bringing rare disease to the attention of biopharma companies.
“This is a critical juncture for our community,” Nadine Hill, executive director of the... |
| 07.01.2015 | Vtesse Raises $25M in Series A Funding | Vtesse, Inc., a Gaithersburg, Maryland-based rare disease company focused on developing drugs for Niemann-Pick Disease Type C (NPC) and other severe diseases, raised $25m in Series A funding.
The round was led by New Enterprise Associates (... |
| 07.01.2015 | Vtesse Launches with $25M Series A |
GAITHERSBURG, MD, Rare disease company focused on developing drugs announced today that it has raised $25 million in Series A funding.
>> Click here for more funding data on Vtesse
>> To export Vtesse funding data to PDF and... |
| - | Rare disease companies must compete for clinical trial participants | As companies turn to rare disease as primary targets for drug development, they’re starting to hit a snag: It’s hard to find a sufficient patient population to test their drugs and, interestingly, must vie against one another to get access ... |
